foto

Dr. M. van der Valk MD PhD

Position
Scientific staff member (UD)
Main activities
Patient care, Research, Teaching
Specialisation
infectious diseases
Focus of research
  1. Improving the understanding and management of co-morbidity and co-infection in people living with HIV

 

Key publications
  • Kooij KW, Wit FWNM, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, Prins M, Reiss P, van der Valk M, Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS 2016;30 (11):1771-1780 [PubMed]
  • van der Valk M, Zaaijer HL, Kater AP, Schinkel J, Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J HEPATOL 2017;66 (1):242-243 [PubMed]
  • Willemse SB, Baak LC, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JTM, Depla ACTM, Tuynman H, van Nieuwkerk CMJ, Schinkel CJ, Kwa D, Reesink HW, van der Valk M, Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J VIRAL HEPATITIS 2016;23 (12):950-954 [PubMed]
  • Nichols BE, Boucher CAB, van der Valk M, Rijnders BJA, van de Vijver DAMC, Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. LANCET INFECT DIS 2016;16 (12):1423-1429 [PubMed]
  • Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P [Contributors: Wit FWNM, van der Valk M, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Prins M, Stolte IG, Martens M, Moll S, Berkel J, Möller L, Visser GR, Welling C, Zaheri S, Hillebregt MMJ, Gras LAJ, Ruijs YMC, Benschop DP, Reiss P, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Ruiz MMM, Girigorie AF, van Leeuwen E, Janssen FR, Heidenrijk M, Schrijver JHN, Zikkenheiner W, Wezel M, Jansen-Kok CSM, Geerlings SE, Godfried MH, Goorhuis A, van der Meer JTM, Nellen FJB, van der Poll T, Prins JM, Wiersinga WJ, van Eden J, Henderiks A, van Hes AMH, Mutschelknauss M, Nobel HE, Pijnappel FJJ, Westerman AM, de Jong J, Postema PG, Bisschop PHLT, Serlie MJM, Lips P, Dekker E, de Rooij SEJA, Willemsen JMR, Vogt L, Portegies P, Schmand BA, Geurtsen GJ , Stege JAt, Twennaar MK, van Eck-Smit BLF, de Jong M, Richel DJ, Verbraak FD, Demirkaya N , Visser I, Ruhé HG, Nieuwkerk PT, van Steenwijk RP, Dijkers E, Majoie CBLM, Caan MWA, Su T, van Lunsen HW, Nievaard MAF, van den Born BJH, Stroes ESG, Mulder WMC]] , Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. CLIN INFECT DIS 2014;59 (12):1787-1797 [PubMed]
All Publications
Research programmes

Improving the understanding and management of co-morbidity and co-infection in people living with HIV

 Since the inception of the AGEhIV cohort study in 2009 I have together with the study PI prof. P. Reiss (Professor of Internal Medicine, in particular the complications of HIV treatment), acted as a senior clinical co-investigator of the study contributing to the design and excecution of a range of studies performed by successive PhD students on the study. (www.agehiv.nl)

 I act as the principal investigator of the MC Free study which aims to eliminate hepatitis C infections in hiv-positive men who have sex with men. 

In line with this implementation research project I am currently initiating together with prof. F. van der Waals (professor in GlobalHealth education) an HIV 'test-and-treat' implementation research project on Bonaire.

Faculty
Dr. M. van der Valk MD PhD

PhD Students
J. Koopsen
T. Prinsenberg
Drs. R. van Zoest MD

Prof. dr. P. Reiss MD PhD (Complications of HIV and HIV treatment)

Other research related activities
  • Membership of editorial board / Editorship, TIJDSCHRIFT VOOR INFECTIEZIEKTEN
Current research funding
  • AbbVie B.V.
  • Amsterdam Inst. for Global Health and Development
  • The Kirby lnstitute, UNSW Australia
  • UMC St. Radboud